JP2001512565A - 疎水性表面への細胞及び生体分子の接着を調節するための組成物及び方法 - Google Patents
疎水性表面への細胞及び生体分子の接着を調節するための組成物及び方法Info
- Publication number
- JP2001512565A JP2001512565A JP53443898A JP53443898A JP2001512565A JP 2001512565 A JP2001512565 A JP 2001512565A JP 53443898 A JP53443898 A JP 53443898A JP 53443898 A JP53443898 A JP 53443898A JP 2001512565 A JP2001512565 A JP 2001512565A
- Authority
- JP
- Japan
- Prior art keywords
- egap
- biomolecule
- bound
- molecule
- organism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 178
- 230000005661 hydrophobic surface Effects 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000009739 binding Methods 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 239000004094 surface-active agent Substances 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 229920001400 block copolymer Polymers 0.000 claims description 45
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 31
- 238000004458 analytical method Methods 0.000 claims description 30
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 29
- 239000012620 biological material Substances 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 230000002209 hydrophobic effect Effects 0.000 claims description 26
- 150000003573 thiols Chemical class 0.000 claims description 23
- 239000003102 growth factor Substances 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 15
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 230000004069 differentiation Effects 0.000 claims description 15
- 235000014633 carbohydrates Nutrition 0.000 claims description 14
- 239000003226 mitogen Substances 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 7
- WGGFHAVVTPGHRD-UHFFFAOYSA-N 2-(pyridin-2-yldisulfanyl)ethanamine Chemical compound NCCSSC1=CC=CC=N1 WGGFHAVVTPGHRD-UHFFFAOYSA-N 0.000 claims description 6
- UHBAPGWWRFVTFS-UHFFFAOYSA-N 4,4'-dipyridyl disulfide Chemical compound C=1C=NC=CC=1SSC1=CC=NC=C1 UHBAPGWWRFVTFS-UHFFFAOYSA-N 0.000 claims description 6
- 108010090804 Streptavidin Proteins 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000008177 pharmaceutical agent Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 4
- 230000001464 adherent effect Effects 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000005291 magnetic effect Effects 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- ROUFCTKIILEETD-UHFFFAOYSA-N 5-nitro-2-[(5-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound N1=CC([N+](=O)[O-])=CC=C1SSC1=CC=C([N+]([O-])=O)C=N1 ROUFCTKIILEETD-UHFFFAOYSA-N 0.000 claims description 2
- 108050001049 Extracellular proteins Proteins 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 2
- UYXQLQUXXCIFQM-UHFFFAOYSA-N 2-hydroxy-1,3,2$l^{5}-dioxaphospholane 2-oxide Chemical compound OP1(=O)OCCO1 UYXQLQUXXCIFQM-UHFFFAOYSA-N 0.000 claims 29
- 102100031869 N-alpha-acetyltransferase 35, NatC auxiliary subunit Human genes 0.000 claims 29
- 101150027985 NAA35 gene Proteins 0.000 claims 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical class ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 230000011278 mitosis Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 17
- 230000021164 cell adhesion Effects 0.000 abstract description 13
- 238000004166 bioassay Methods 0.000 abstract description 8
- 230000010261 cell growth Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 131
- 108010067306 Fibronectins Proteins 0.000 description 30
- 102000016359 Fibronectins Human genes 0.000 description 30
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 30
- 239000004793 Polystyrene Substances 0.000 description 26
- 239000000758 substrate Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 19
- 210000002744 extracellular matrix Anatomy 0.000 description 18
- VOESDNNEDODLBS-XSLAGTTESA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(2s)-1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VOESDNNEDODLBS-XSLAGTTESA-N 0.000 description 17
- 108010034534 glycyl-arginyl-glycyl-aspartyl-seryl-tyrosine Proteins 0.000 description 17
- 229920002223 polystyrene Polymers 0.000 description 17
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 15
- -1 polyethylene Polymers 0.000 description 15
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 13
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 229920001983 poloxamer Polymers 0.000 description 13
- 101150079978 AGRN gene Proteins 0.000 description 12
- 102100040026 Agrin Human genes 0.000 description 12
- 108700019743 Agrin Proteins 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 238000001179 sorption measurement Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 10
- 102000008100 Human Serum Albumin Human genes 0.000 description 10
- 108091006905 Human Serum Albumin Proteins 0.000 description 10
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 108010084389 glycyltryptophan Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- AJHCSUXXECOXOY-NSHDSACASA-N Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-NSHDSACASA-N 0.000 description 8
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000004816 latex Substances 0.000 description 8
- 229920000126 latex Polymers 0.000 description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 102000006495 integrins Human genes 0.000 description 7
- 108010044426 integrins Proteins 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 6
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- RGNVSYKVCGAEHK-GUBZILKMSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O RGNVSYKVCGAEHK-GUBZILKMSA-N 0.000 description 5
- 102000004266 Collagen Type IV Human genes 0.000 description 5
- 108010042086 Collagen Type IV Proteins 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 4
- 108050007957 Cadherin Proteins 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 4
- 229920002971 Heparan sulfate Polymers 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 108010034892 glycyl-arginyl-glycyl-aspartyl-serine Proteins 0.000 description 4
- 229920001600 hydrophobic polymer Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229960003080 taurine Drugs 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 102000035160 transmembrane proteins Human genes 0.000 description 4
- 108091005703 transmembrane proteins Proteins 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 3
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 3
- MISJXUDJCSZFAH-UHFFFAOYSA-N 1-sulfanylpyridin-2-one Chemical compound SN1C=CC=CC1=O MISJXUDJCSZFAH-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 101000802896 Dendroaspis angusticeps Dendrotoxin A Proteins 0.000 description 3
- 101000802897 Dendroaspis polylepis polylepis Acetylcholinesterase toxin C Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 3
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000715 neuromuscular junction Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 108010008217 nidogen Proteins 0.000 description 3
- 238000005375 photometry Methods 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920002239 polyacrylonitrile Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- KYRUKRFVOACELK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl)propanoate Chemical compound C1=CC(O)=CC=C1CCC(=O)ON1C(=O)CCC1=O KYRUKRFVOACELK-UHFFFAOYSA-N 0.000 description 2
- ZNUKSRFJVSGOTL-UHFFFAOYSA-N 1-nitro-4-(trichloromethyl)benzene Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)(Cl)Cl)C=C1 ZNUKSRFJVSGOTL-UHFFFAOYSA-N 0.000 description 2
- HOHIAEPXOHCCGW-UHFFFAOYSA-N 2-aminoethanesulfonic acid Chemical compound NCCS(O)(=O)=O.NCCS(O)(=O)=O HOHIAEPXOHCCGW-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- GSASOFRDSIKDSN-UHFFFAOYSA-N 6-[(5-carboxypyridin-2-yl)disulfanyl]pyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1SSC1=CC=C(C(O)=O)C=N1 GSASOFRDSIKDSN-UHFFFAOYSA-N 0.000 description 2
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- 108010062802 CD66 antigens Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 102100024342 Contactin-2 Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 101000802894 Dendroaspis angusticeps Fasciculin-2 Proteins 0.000 description 2
- 102000011799 Desmoglein Human genes 0.000 description 2
- 108050002238 Desmoglein Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 2
- 101000909516 Homo sapiens Contactin-2 Proteins 0.000 description 2
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 description 2
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 description 2
- 102100022339 Integrin alpha-L Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 101710089162 Neuroglian Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 108050006823 Selectin superfamily Proteins 0.000 description 2
- 102000019318 Selectin superfamily Human genes 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100022791 Sodium/potassium-transporting ATPase subunit beta-2 Human genes 0.000 description 2
- 101710193880 Sodium/potassium-transporting ATPase subunit beta-2 Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108090000054 Syndecan-2 Proteins 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- RAURUSFBVQLAPW-DNIKMYEQSA-N clocinnamox Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)NC(=O)\C=C\C=2C=CC(Cl)=CC=2)CC1)O)CC1CC1 RAURUSFBVQLAPW-DNIKMYEQSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000005732 intercellular adhesion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000034005 thiol-disulfide exchange Effects 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- UMZVBZDHGKJFGQ-UHFFFAOYSA-N 1-[2-[[2-[[2-[[2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCCC(NC(=O)CN)C(=O)NCC(=O)NC(CC(O)=O)C(=O)NC(C(O)C)C(=O)N1CCCC1C(O)=O UMZVBZDHGKJFGQ-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- AQYNZOSCOWGGTP-UHFFFAOYSA-N 2-pyridin-2-ylsulfanylpyridine Chemical group C=1C=CC=NC=1SC1=CC=CC=N1 AQYNZOSCOWGGTP-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102100036601 Aggrecan core protein Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102000014464 Chemokine CX3CL1 Human genes 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000009842 Fibril-Associated Collagens Human genes 0.000 description 1
- 108010020305 Fibril-Associated Collagens Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 108010013996 Fibromodulin Proteins 0.000 description 1
- 102000017177 Fibromodulin Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 102000003711 Syndecan-2 Human genes 0.000 description 1
- 102100028644 Tenascin-R Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101710098414 Tyrosine-protein phosphatase Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108010073374 agrin receptor Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000032341 cell morphogenesis Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 108010000421 fibronectin attachment peptide Proteins 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108700041430 link Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- VMPVHFKMKZVFEO-UHFFFAOYSA-N n-(pyridin-2-yldisulfanyl)ethanamine Chemical group CCNSSC1=CC=CC=N1 VMPVHFKMKZVFEO-UHFFFAOYSA-N 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 102000005162 pleiotrophin Human genes 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- DGYNEKPTRLXGTP-UHFFFAOYSA-N propane-1,3-diamine Chemical compound NCCCN.NCCCN DGYNEKPTRLXGTP-UHFFFAOYSA-N 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 102000015340 serglycin Human genes 0.000 description 1
- 108010050065 serglycin Proteins 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 108010020387 tenascin R Proteins 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 125000005413 thiopyridyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000002233 tyrosyl group Chemical group 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/823—Immunogenic carrier or carrier per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/784,203 US6284503B1 (en) | 1993-08-20 | 1997-01-15 | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
| PCT/US1998/000337 WO1998031734A1 (en) | 1997-01-15 | 1998-01-15 | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001512565A true JP2001512565A (ja) | 2001-08-21 |
| JP2001512565A5 JP2001512565A5 (enExample) | 2006-01-05 |
Family
ID=25131669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53443898A Pending JP2001512565A (ja) | 1997-01-15 | 1998-01-15 | 疎水性表面への細胞及び生体分子の接着を調節するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6284503B1 (enExample) |
| EP (1) | EP1002066B1 (enExample) |
| JP (1) | JP2001512565A (enExample) |
| KR (1) | KR20000070229A (enExample) |
| AT (1) | ATE501249T1 (enExample) |
| AU (1) | AU740877B2 (enExample) |
| CA (1) | CA2277995C (enExample) |
| DE (1) | DE69842166D1 (enExample) |
| IL (2) | IL130961A0 (enExample) |
| WO (1) | WO1998031734A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001083162A (ja) * | 1999-09-17 | 2001-03-30 | Fuji Photo Film Co Ltd | 膜状生体高分子吸着材及び吸着用キット |
| JP2020038059A (ja) * | 2017-08-31 | 2020-03-12 | 東洋インキＳｃホールディングス株式会社 | 蛋白質、細胞又は微生物の接着抑制剤、並びにその用途 |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284503B1 (en) * | 1993-08-20 | 2001-09-04 | University Of Utah Research Foundation | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
| CA2286590C (en) * | 1997-04-18 | 2005-08-02 | California Institute Of Technology | Multifunctional polymeric tissue coatings |
| DE19748489A1 (de) * | 1997-11-03 | 1999-05-06 | Roche Diagnostics Gmbh | Polyethylenglykol-derivatisierte Biomoleküle und deren Verwendung in heterogenen Nachweisverfahren |
| AR021240A1 (es) * | 1998-11-13 | 2002-07-03 | Commw Scient Ind Res Org | Peptidos acoplados |
| WO2000065352A1 (en) * | 1999-04-28 | 2000-11-02 | Eidgenossisch Technische Hochschule Zurich | Polyionic coatings in analytic and sensor devices |
| US7220276B1 (en) * | 2000-03-06 | 2007-05-22 | Surmodics, Inc. | Endovascular graft coatings |
| US6706479B2 (en) * | 2000-10-05 | 2004-03-16 | Virginia Tech Intellectual Properties, Inc. | Bio-chip, photoluminescent methods for identifying biological material, and apparatuses for use with such methods and bio-chips |
| AU2002211736A1 (en) * | 2000-10-13 | 2002-04-22 | University Of Cincinnati | Methods for synthesizing precipitated silica and use thereof |
| DE10100961B4 (de) | 2001-01-11 | 2005-08-04 | Polyzenix Gmbh | Körperverträglicher Werkstoff und mit diesem Werkstoff beschichtetes Substrat für die Züchtung von Zellen und künstlichen aus Zellen aufgebauten oder gewachsenen organischen Implantaten |
| US9080146B2 (en) | 2001-01-11 | 2015-07-14 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
| AU2002305924A1 (en) | 2001-02-02 | 2002-10-08 | Allvivo, Inc. | End group activated polymers with oligonucleotide ligands |
| US20050244843A1 (en) * | 2001-11-16 | 2005-11-03 | Wen-Tien Chen | Blood test prototypes and methods for the detection of circulating tumor and endothelial cells |
| US20030148017A1 (en) * | 2001-12-07 | 2003-08-07 | Olli Tuominen | Copolymer coating for a hydrophobic membrane |
| CA2448513A1 (en) * | 2002-06-29 | 2003-12-29 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Isoflavone concentrates, as well as methods for their production |
| US8227411B2 (en) * | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
| US7598224B2 (en) * | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
| US7166574B2 (en) | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
| US20050059140A1 (en) * | 2003-09-12 | 2005-03-17 | Andrea Liebmann-Vinson | Methods of surface modification to enhance cell adhesion |
| DE10358565B4 (de) * | 2003-12-15 | 2007-06-28 | P.A.L.M. Microlaser Technologies Ag | Aufnahmeelement zum Aufnehmen eines aus einer biologischen Masse mittels Laserstrahlung herausgelösten Objekts und Verfahren zur Gewinnung und Verarbeitung eines biologischen Objekts |
| US7414028B1 (en) * | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
| US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
| US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
| US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| US7528105B1 (en) | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
| ATE482228T1 (de) | 2004-02-20 | 2010-10-15 | Biosurface Eng Tech Inc | Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2) |
| US20080268013A1 (en) * | 2005-02-10 | 2008-10-30 | Emory University | Polyethylene Oxide Polymers Including Anti-Inflammatory Glycodendrons |
| EP1712284B1 (en) * | 2005-04-15 | 2012-10-10 | Samsung Electronics Co., Ltd. | Cell separation method using hydrophobic solid supports |
| US7749701B2 (en) * | 2005-08-11 | 2010-07-06 | Agilent Technologies, Inc. | Controlling use of oligonucleotide sequences released from arrays |
| DE102005040211B4 (de) | 2005-08-16 | 2010-02-11 | Maquet Cardiopulmonary Ag | Verwendung von nichtionischen Estern in einer Beschichtung für mit Blut in Kontakt kommende Oberflächen und medizinische Vorrichtung |
| US20070225795A1 (en) * | 2006-03-24 | 2007-09-27 | Juan Granada | Composite vascular prosthesis |
| US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
| WO2007150053A2 (en) | 2006-06-22 | 2007-12-27 | Biosurface Engineering Technologies, Inc. | Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis |
| KR101457716B1 (ko) * | 2006-11-01 | 2014-11-03 | 베크만 컬터, 인코포레이티드 | 친화도 분석을 위한 결합 표면 |
| US20080187188A1 (en) * | 2007-02-07 | 2008-08-07 | Oleg Beletski | Systems, apparatuses and methods for facilitating efficient recognition of delivered content |
| EP2497505B1 (en) * | 2007-04-16 | 2016-08-10 | Regentis Biomaterials Ltd. | Compositions and methods for scaffold formation |
| AU2008289178A1 (en) * | 2007-08-16 | 2009-02-26 | Carnegie Mellon University | Inflammation-regulating compositions and methods |
| SG188096A1 (en) | 2008-01-30 | 2013-03-28 | Geron Corp | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| US8329469B2 (en) | 2008-01-30 | 2012-12-11 | Geron Corporation | Swellable (meth)acrylate surfaces for culturing cells in chemically defined media |
| SG188098A1 (en) | 2008-01-30 | 2013-03-28 | Geron Corp | Synthetic surfaces for culturing stem cell derived cardiomyocytes |
| AU2009210765A1 (en) | 2008-01-30 | 2009-08-13 | Geron Corporation | Synthetic surfaces for culturing cells in chemically defined media |
| DE102008027133A1 (de) * | 2008-05-30 | 2009-12-03 | Ls Medcap Gmbh | Vollsynthetisches Albumin-Analogon |
| WO2010036257A1 (en) * | 2008-09-25 | 2010-04-01 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
| EP2442839B1 (en) | 2009-04-09 | 2017-10-04 | The University of Queensland | Block copolymer blends |
| DE102009040880B4 (de) * | 2009-09-09 | 2012-10-18 | Andreas Hettich Gmbh & Co. Kg | Vorrichtung zur Durchführung von Tests zur Hämostase |
| WO2011063128A1 (en) * | 2009-11-18 | 2011-05-26 | Affinergy, Inc. | Implantable bone graft materials |
| CA2849987C (en) * | 2011-09-30 | 2023-03-14 | Wake Forest University Health Sciences | Bioscaffolds for formation of motor endplates and other specialized tissue structures |
| JP6875670B2 (ja) * | 2016-06-27 | 2021-05-26 | ユニバーシティ オブ ルーイビル リサーチ ファウンデーション，インコーポレーテッド | 生体関連物質を含有する球状体および関係する方法 |
| US10269569B2 (en) * | 2016-11-29 | 2019-04-23 | Taiwan Semiconductor Manufacturing Company, Ltd. | Semiconductor device and methods of manufacture |
| US10941274B1 (en) | 2020-09-01 | 2021-03-09 | King Abdulaziz University | Nanoparticle-infused ABS filament for 3D-printed materials and uses for neutron detection and discrimination |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4264766A (en) | 1877-09-19 | 1981-04-28 | Hoffmann-La Roche Inc. | Immunological diagnostic reagents |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| SE420733B (sv) | 1974-05-30 | 1981-10-26 | Exploaterings Ab Tbf | Gelprodukt, innehallande tiosulfatgrupper samt sett for framstellning derav |
| US3966580A (en) | 1974-09-16 | 1976-06-29 | The University Of Utah | Novel protein-immobilizing hydrophobic polymeric membrane, process for producing same and apparatus employing same |
| SE430062B (sv) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
| DE2850058A1 (de) | 1978-11-18 | 1980-05-29 | Bayer Ag | Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4259474A (en) | 1979-09-25 | 1981-03-31 | Gaf Corporation | Sulfur-containing polyoxyalkylenes |
| SE8102194L (sv) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| DE3532626A1 (de) | 1985-09-12 | 1987-03-19 | Boehringer Mannheim Gmbh | Verfahren zur bestimmung eines partners einer immunreaktion |
| DE3532593A1 (de) | 1985-09-12 | 1987-03-12 | Koemmerling Kunststoff | Extrudierter kunststoffhohlprofilstab fuer rahmen von fenstern und tueren |
| WO1987006007A1 (en) | 1986-03-28 | 1987-10-09 | Toray Industries, Inc. | Immobilized physiologically active material |
| US5567859A (en) | 1991-03-19 | 1996-10-22 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| US5674911A (en) | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
| IE64284B1 (en) | 1987-08-03 | 1995-07-26 | Ddi Pharmaceuticals | Conjugates of superoxide dismutase |
| US5006333A (en) | 1987-08-03 | 1991-04-09 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US4929510A (en) | 1988-04-29 | 1990-05-29 | State University Of New York | Biocompatible polymer articles |
| US5248820A (en) | 1989-02-21 | 1993-09-28 | Pfizer Inc. | Crystalline N-(S-3-methylheptanoyl)-D-gamma-glutamyl-glycyl-D-alanine, and processes and intermediates therefor |
| CA2028804C (en) | 1989-11-21 | 2000-06-20 | Howard J. Buttery | Biomosaic polymers and method for preparing same |
| US5219926A (en) | 1989-12-29 | 1993-06-15 | Berol Nobel Ab | Method of covalently bonding biopolymer to a solid hydrophilic organic polymer |
| AU1676992A (en) | 1991-03-18 | 1992-10-21 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US5516703A (en) * | 1993-08-20 | 1996-05-14 | The University Of Utah | Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands |
| US6284503B1 (en) | 1993-08-20 | 2001-09-04 | University Of Utah Research Foundation | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
| BE1008955A3 (fr) | 1994-11-14 | 1996-10-01 | Univ Catholique Louvain | Procede d'obtention de biomateriaux et produits obtenus. |
| US5783178A (en) | 1994-11-18 | 1998-07-21 | Supratek Pharma. Inc. | Polymer linked biological agents |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
-
1997
- 1997-01-15 US US08/784,203 patent/US6284503B1/en not_active Expired - Lifetime
-
1998
- 1998-01-15 IL IL13096198A patent/IL130961A0/xx active IP Right Grant
- 1998-01-15 CA CA002277995A patent/CA2277995C/en not_active Expired - Fee Related
- 1998-01-15 AU AU60182/98A patent/AU740877B2/en not_active Expired
- 1998-01-15 DE DE69842166T patent/DE69842166D1/de not_active Expired - Lifetime
- 1998-01-15 JP JP53443898A patent/JP2001512565A/ja active Pending
- 1998-01-15 EP EP98903402A patent/EP1002066B1/en not_active Expired - Lifetime
- 1998-01-15 AT AT98903402T patent/ATE501249T1/de not_active IP Right Cessation
- 1998-01-15 KR KR1019997006456A patent/KR20000070229A/ko not_active Withdrawn
- 1998-01-15 WO PCT/US1998/000337 patent/WO1998031734A1/en not_active Ceased
-
1999
- 1999-07-14 IL IL130961A patent/IL130961A/en not_active IP Right Cessation
-
2001
- 2001-09-04 US US09/946,079 patent/US6670199B2/en not_active Expired - Fee Related
-
2003
- 2003-12-30 US US10/748,061 patent/US7208299B2/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001083162A (ja) * | 1999-09-17 | 2001-03-30 | Fuji Photo Film Co Ltd | 膜状生体高分子吸着材及び吸着用キット |
| JP2020038059A (ja) * | 2017-08-31 | 2020-03-12 | 東洋インキＳｃホールディングス株式会社 | 蛋白質、細胞又は微生物の接着抑制剤、並びにその用途 |
| JP7192314B2 (ja) | 2017-08-31 | 2022-12-20 | 東洋インキＳｃホールディングス株式会社 | 蛋白質、細胞又は微生物の接着抑制剤、並びにその用途 |
| JP2023027114A (ja) * | 2017-08-31 | 2023-03-01 | 東洋インキＳｃホールディングス株式会社 | 蛋白質、細胞又は微生物の接着抑制剤、並びにその用途 |
| JP7425946B2 (ja) | 2017-08-31 | 2024-02-01 | ａｒｔｉｅｎｃｅ株式会社 | 蛋白質、細胞又は微生物の接着抑制剤、並びにその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE501249T1 (de) | 2011-03-15 |
| US20020019037A1 (en) | 2002-02-14 |
| CA2277995C (en) | 2003-03-18 |
| US7208299B2 (en) | 2007-04-24 |
| US6284503B1 (en) | 2001-09-04 |
| US20040170964A1 (en) | 2004-09-02 |
| AU740877B2 (en) | 2001-11-15 |
| DE69842166D1 (de) | 2011-04-21 |
| IL130961A0 (en) | 2001-01-28 |
| WO1998031734A1 (en) | 1998-07-23 |
| EP1002066B1 (en) | 2011-03-09 |
| EP1002066A4 (en) | 2004-12-01 |
| KR20000070229A (ko) | 2000-11-25 |
| US6670199B2 (en) | 2003-12-30 |
| AU6018298A (en) | 1998-08-07 |
| CA2277995A1 (en) | 1998-07-23 |
| EP1002066A1 (en) | 2000-05-24 |
| IL130961A (en) | 2009-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001512565A (ja) | 疎水性表面への細胞及び生体分子の接着を調節するための組成物及び方法 | |
| US6368877B1 (en) | Self-assembling peptide surfaces for cell patterning and interactions | |
| CA2058515C (en) | Method of preparing biologically active reagents from succinimide-containing polymers, analytical element and methods of use | |
| AU654833B2 (en) | The use of pairs of peptides with extremely high specific affinity for one another in the area of in vitro diagnosis | |
| JPH08507806A (ja) | 高分子の微粒子および調製法 | |
| JP4284412B2 (ja) | 細胞およびリポソームの固定化体とその固定化方法 | |
| JP3840521B2 (ja) | ウイルス検出方法およびウイルス検査用キット | |
| US6379952B1 (en) | Method for cell selection utilizing azlactone-functional supports | |
| US7645721B2 (en) | End group activated polymers with oligonucleotide ligands | |
| JPS6069100A (ja) | 担体上への生物学的高分子の固定法 | |
| JPH02129550A (ja) | 固相指示薬の赤血球およびその調製法 | |
| NL8301464A (nl) | Geimmobiliseerd adult t-cel leukemie antigen, werkwijze voor het bereiden daarvan en methode voor het bepalen van een antilichaam daarmee. | |
| Hoffman | Immobilization of biomolecules and cells on and within polymeric biomaterials | |
| CZ276295A3 (en) | Immune nanoparticles carrying anti-cd-4 monoclonal antibodies and the use thereof for prophylaxis and/or treating pathologic states caused by infection with hiv viruses or as biological reaction substances | |
| AU636001B2 (en) | Method of covalently bonding proteins to hydrophilic surfaces | |
| JPH0757760B2 (ja) | 生体由来物質の固定化方法 | |
| US20060084159A1 (en) | Method for manufacturing of three dimensional composite surfaces for microarrays | |
| JP2006329976A (ja) | 蛍光標識体 | |
| JP5258012B2 (ja) | 新規なｒａｎｋｌ−グリコサミノグリカン結合体、及び該活性調節剤。 | |
| JPH04204257A (ja) | 感染症患者に特異的に出現する抗体の検出法及びそれに用いるキット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20050114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060313 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060508 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060609 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20060607 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061114 |